Merck Beats Q2 Earnings Expectations Despite Acquisition Charges

Merck's second-quarter earnings report exceeded market expectations, driven by robust sales of new products. The company posted a net loss of $1.34 billion for the quarter, but its revenue grew by 5% to $16.61 billion.

The pharmaceutical giant's Keytruda, an immunotherapy treatment, generated $8.37 billion in sales during the second quarter, up 5% from the same period last year. Merck also saw strong growth from newer products such as Winrevair, which treats a rare lung condition, and Capvaxive, its pneumococcal vaccine.

However, Merck's profit guidance was reduced due to charges related to its acquisition of Terns Pharmaceuticals and Cidara Therapeutics. The company now expects adjusted earnings between $2.66 and $2.76 per share, down from a previous range of $5.04 to $5.16 per share.